Endogenous Human Proteins Interfering with Amyloid FormationShow others and affiliations
2022 (English)In: Biomolecules, E-ISSN 2218-273X, Vol. 12, no 3, article id 446
Article, review/survey (Refereed) Published
Abstract [en]
Amyloid formation is a pathological process associated with a wide range of degenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and diabetes mellitus type 2. During disease progression, abnormal accumulation and deposition of proteinaceous material are accompanied by tissue degradation, inflammation, and dysfunction. Agents that can interfere with the process of amyloid formation or target already formed amyloid assemblies are consequently of therapeutic interest. In this context, a few endogenous proteins have been associated with an anti-amyloidogenic activity. Here, we review the properties of transthyretin, apolipoprotein E, clusterin, and BRICHOS protein domain which all effectively interfere with amyloid in vitro, as well as displaying a clinical impact in humans or animal models. Their involvement in the amyloid formation process is discussed, which may aid and inspire new strategies for therapeutic interventions.
Place, publisher, year, edition, pages
MDPI, 2022. Vol. 12, no 3, article id 446
Keywords [en]
Alpha-synuclein, Amyloid inhibition, Amyloid-beta, Apolipoprotein E, BRICHOS, Clusterin, Endogenous proteins, IAPP, Transthyretin
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:umu:diva-193407DOI: 10.3390/biom12030446ISI: 000775848600001Scopus ID: 2-s2.0-85126704016OAI: oai:DiVA.org:umu-193407DiVA, id: diva2:1648566
2022-03-312022-03-312023-09-05Bibliographically approved